Captrust Financial Advisors Provectus Biopharmaceuticals, Inc. Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	BUY	$0.05 - $0.07 $1,862 - $2,607	37,257 Added 182.61%	57,659 $3,000
Q1 2022 May 16, 2022	SELL	$0.06 - $0.07 $1,335 - $1,557	-22,257 Reduced 52.17%	20,402 $1,000
Q4 2021 Feb 14, 2022	BUY	$0.05 - $0.06 $1,010 - $1,212	20,202 Added 89.96%	42,659 $2,000
Q4 2020 Feb 16, 2021	BUY	$0.06 - $0.09 $1,347 - $2,021	22,457 New	22,457 $1,000
Q3 2020 Nov 17, 2020	SELL	$0.04 - $0.1 $866 - $2,165	-21,657 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$0.04 - $0.06 $866 - $1,299	21,657 New	21,657 $1,000

227K

Ticker PVCT
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 419,496,992
Market Cap $50.3M
Description
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.